Akari Therapeutics (AKTX) Amortization - Intangibles (2015)

Akari Therapeutics (AKTX) reported Amortization - Intangibles of $19.3 million for Q3 2015.

Akari Therapeutics (AKTX) Amortization - Intangibles (2015) Analysis & Trends

Akari Therapeutics (AKTX) has 1 years of Amortization - Intangibles data on file, last reported at $19.3 million in Q3 2015.

For the quarter ending Q3 2015, Amortization - Intangibles changed N/A year-over-year to $19.3 million; the trailing twelve-month figure through Dec 2015 stood at $19.3 million (changed N/A YoY), and the FY2015 full-year result was $19.3 million, changed N/A from the prior year.
Amortization - Intangibles held at $19.3 million in Q3 2015.
In the past five years, Amortization - Intangibles ranged from a high of $19.3 million in Q3 2015 to a low of $19.3 million in Q3 2015.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	Alnylam Pharmaceuticals	36.08 Bn	33.07 Bn	959.66 Mn

Download Data

Date	Value
Sep 30, 2015	19.28 Mn